Published online before print April 28, 2005, doi: 10.1161/01.ATV.0000168414.06853.f0
© 2005 American Heart Association, Inc.
Vascular Biology |
Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension
From the Divisions of Nephrology (J.T.K., G.H., D.F.) and Respiratory Medicine (A.T., M.M.H.), Department of Internal Medicine, Medical School Hannover, Germany; and the Institute of Clinical Pharmacology (S.M.B.-B., J.M.-L.), "Otto-von-Guericke" University, Magdeburg, Germany.
Correspondence to J.T. Kielstein, MD, Department of Internal Medicine, Division of Nephrology, Medical School Hannover Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. E-mail Kielstein{at}yahoo.com
Objective— We explored the potential role of the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) in patients with idiopathic pulmonary arterial hypertension (IPAH).
Method and Results— We correlated plasma ADMA levels and cardiovascular indices from right heart catheterization in 57 patients with IPAH. Predictors of survival in patients with IPAH were studied. Furthermore, the effect of systemic ADMA infusion on pulmonary ventricular resistance and stroke volume was investigated in healthy volunteers using right heart catheterization. Mean plasma ADMA concentrations were significantly higher in patients with IPAH than in control subjects (0.53±0.15 versus 0.36±0.05 µmol/L; P<0.001). ADMA plasma concentrations correlated significantly with indices of right ventricular function, such as mixed-venous oxygen saturation (r=–0.49; P<0.0001), right atrial pressure (r=0.39; P<0.003), cardiac index (r=–0.35; P<0.008), as well as survival (r=–0.47; P<0.0001). Multiple regression analysis revealed that right atrial pressure (r=0.31; P<0.026) and ADMA (r=0.29; P<0.039) were independent predictors of mortality. Moreover, patients with supra-median plasma ADMA levels had significantly (P<0.021) worse survival than patients with infra-median ADMA values. ADMA infusion in healthy volunteers increased pulmonary vascular resistance (68.9±7.6 versus 95.6±6.3 dyne · s · cm–5; P<0.05) and decreased stroke volume (101.1±6.7 mL versus 95.6±6.3 mL; P<0.05).
Conclusion— Increased ADMA plasma levels are associated with unfavorable pulmonary hemodynamics and worse outcome in patients with IPAH.
We explored the role of the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) in idiopathic pulmonary arterial hypertension (IPAH). Plasma ADMA levels correlated significantly with right atrial pressure, cardiac index, and mixed-venous oxygen saturation. Moreover, ADMA was an independent predictor of survival in patient with IPAH.
Key Words: idiopathic pulmonary arterial hypertension • ADMA • nitric oxide
This article has been cited by other articles:
 |
|
 |
|
  P. P. Landburg, T. Teerlink, E. J. van Beers, F. A.J. Muskiet, M. C. Kappers-Klunne, J. W.J. van Esser, M. R. Mac Gillavry, B. J. Biemond, D. P.M. Brandjes, A. J. Duits, et al. Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension Haematologica, September 1, 2008; 93(9): 1410 - 1412. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dimitroulas, G. Giannakoulas, T. Sfetsios, H. Karvounis, H. Dimitroula, G. Koliakos, and L. Settas Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension Rheumatology, August 27, 2008; (2008) ken346v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Warwick, P. S. Thomas, and D. H. Yates Biomarkers in pulmonary hypertension Eur. Respir. J., August 1, 2008; 32(2): 503 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-P. Diller, S. van Eijl, D. O. Okonko, L. S. Howard, O. Ali, T. Thum, S. J. Wort, E. Bedard, J. S. R. Gibbs, J. Bauersachs, et al. Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension Circulation, June 10, 2008; 117(23): 3020 - 3030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Skoro-Sajer, F. Mittermayer, A. Panzenboeck, D. Bonderman, R. Sadushi, R. Hitsch, J. Jakowitsch, W. Klepetko, M. P. Kneussl, M. Wolzt, et al. Asymmetric Dimethylarginine Is Increased in Chronic Thromboembolic Pulmonary Hypertension Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1154 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Coggins and K. D. Bloch Nitric Oxide in the Pulmonary Vasculature Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1877 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Duckelmann, F. Mittermayer, D. G. Haider, J. Altenberger, J. Eichinger, and M. Wolzt Asymmetric Dimethylarginine Enhances Cardiovascular Risk Prediction in Patients With Chronic Heart Failure Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2037 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jain, H. Ventura, and B. deBoisblanc Pathophysiology of Pulmonary Arterial Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 104 - 109. [Abstract] [PDF]
|
|
|
|
 |
|
 J. T. Kielstein and C. Zoccali A New Perspective for the Treatment of Renal Diseases? J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1365 - 1367. [Full Text] [PDF]
|
|
|
|
|
|
G. Hansmann, R. A. Wagner, S. Schellong, V. A. de Jesus Perez, T. Urashima, L. Wang, A. Y. Sheikh, R. S. Suen, D. J. Stewart, and M. Rabinovitch Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator-Activated Receptor-{gamma} Activation Circulation, March 13, 2007; 115(10): 1275 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Meinitzer, U. Seelhorst, B. Wellnitz, G. Halwachs-Baumann, B. O. Boehm, B. R. Winkelmann, and W. Marz Asymmetrical Dimethylarginine Independently Predicts Total and Cardiovascular Mortality in Individuals with Angiographic Coronary Artery Disease (The Ludwigshafen Risk and Cardiovascular Health Study) Clin. Chem., February 1, 2007; 53(2): 273 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bulau, D. Zakrzewicz, K. Kitowska, J. Leiper, A. Gunther, F. Grimminger, and O. Eickelberg Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L18 - L24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Yildirim, P. Bulau, D. Zakrzewicz, K. E. Kitowska, N. Weissmann, F. Grimminger, R. E. Morty, and O. Eickelberg Increased Protein Arginine Methylation in Chronic Hypoxia: Role of Protein Arginine Methyltransferases Am. J. Respir. Cell Mol. Biol., October 1, 2006; 35(4): 436 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Bode-Boger, F. Scalera, J. T. Kielstein, J. Martens-Lobenhoffer, G. Breithardt, M. Fobker, and H. Reinecke Symmetrical Dimethylarginine: A New Combined Parameter for Renal Function and Extent of Coronary Artery Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1128 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper and L. J. Rubin Update in pulmonary hypertension 2005. Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 499 - 505. [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Kielstein and J. P. Cooke Arginine Metabolism, Pulmonary Hypertension, and Sickle Cell Disease JAMA, November 16, 2005; 294(19): 2433 - 2433. [Full Text] [PDF]
|
|